血尿酸、CysC及Hcy与老年帕金森病患者病程及疾病严重程度相关性分析

Abstract
Figure/Table
References (26)
Related Citation (15)

Download: PDF (520 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To analyze the correlation of blood uric acid (UA), cystatin C (CysC), and homocysteine (Hcy) with the course and severity of disease in elderly patients with Parkinson disease. Methods Eighty-six elderly Parkinson disease patients admitted to Affiliated Ruici Hospital of Nantong University from January 2018 to January 2021 were selected. They were divided into <6 years group (45 cases), 6-10 years group (28 cases), and >10 years group (13 cases) according to the course of the disease; they were divided into mild group (25 cases), moderate group (43 cases), and severe group (48 cases) according to the Hoehn-Yahr grading scale. Serum UA, CysC, and Hcy levels in patients with different courses of disease and different severity of disease were compared, and the correlation between serum UA, CysC, and Hcy levels and the course of disease and severity of disease were analyzed by Spearman correlation analysis. Results The serum UA level in >10 years group was lower than that in 6-10 years group and <6 years group; the serum UA level in 6-10 years group was lower than that in <6 years group, and the differences were statistically significant (P < 0.05). The levels of serum CysC and Hcy in >10 years group were higher than those in 6-10 years group and <6 years group; and the levels of serum CysC and Hcy in 6-10 years group were higher than those in <6 years group, and the differences were statistically significant (P < 0.05). The serum UA level in severe group was lower than that in moderate group and mild group; the serum UA level in moderate group was lower than that in mild group, and the differences were statistically significant (P < 0.05). The levels of serum CysC and Hcy in severe group were higher than those in moderate group and mild group; and the levels of serum CysC and Hcy in moderate group were higher than those in mild group, and the differences were statistically significant (P < 0.05). Serum UA level was negatively correlated with the course of disease (P < 0.05); serum CysC and Hcy levels were positively correlated with the course of disease and severity of disease (P < 0.05). Conclusion The changes of serum UA, CysC, and Hcy levels in elderly patients with Parkinson disease with different course and severity of disease are significant, clinical monitoring of the changes of serum UA, CysC, and Hcy levels is of great importance for prevention and treatment and control of disease development.

Key words： Parkinson disease Uric acid Cystatin C Homocysteine Course of disease Severity

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Jiahe1 KE Kaifu2 SHI Jiansheng2 ZHANG Qi1

Cite this article:

ZHANG Jiahe1 KE Kaifu2 SHI Jiansheng2 ZHANG Qi1. Correlation analysis of serum uric acid, CysC, and Hcy with the course and severity of disease in elderly patients with Parkinson disease#br#[J]. 中国医药导报, 2022, 19(5): 82-85.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I5/82

[1] Simonet C，Tolosa E，Camara A，et al. Emergencies and critical issues in Parkinson’s disease [J]. Pract Neurol，2020，20（1）：15-25.
[2] 尤林，白抚生，韩艳丽，等.帕金森病患者睡眠障碍临床特点及相关因素[J].中国公共卫生，2018，34（1）：133-134.
[3] Alexoudi A，Alexoudi I，Gatzonis S. Parkinson’s disease pathogenesis，evolution and alternative pathways：A review [J]. Rev Neurol（Paris），2018，174（10）：699-704.
[4] 李波，徐世成，赵安容.帕金森患者同型半胱氨酸、血尿酸水平变化及其与认知功能状况相关性[J].临床军医杂志，2020，48（2）：179-180.
[5] Li J，Gu C，Zhu M，et al. Correlations between blood lipid，serum cystatin C，and homocysteine levels in patients with Parkinson’s disease [J]. Psychogeriatrics，2020，20（2）：180-188.
[6] 常庆庆，李红燕.帕金森病患者血脂、胱抑素C及同型半胱氨酸水平分析[J].中国临床神经科学，2018，26（5）：22-28.
[7] 杨旭，季一飞，张珊珊，等.血浆同型半胱氨酸和血尿酸水平在帕金森病中的作用[J].西部医学，2018，30（2）：201-204.
[8] 李哲.帕金森病[M].苏州：江苏科学技术出版社，2011：98-101.
[9] 刘军.中国帕金森病的诊断标准（2016版）[J].中华神经科杂志，2016，49（4）：268-271.
[10] Raza C，Anjum R，Shakeel NUA. Parkinson’s disease：Mechanisms，translational models and management strategies [J]. Life Sci，2019，226（3）：77-90.
[11] 夏欢，罗琴，王玉玲，等.帕金森病多巴胺细胞凋亡与Fas基因表达的机制研究[J].中国医药导报，2019，16（34）：4-6.
[12] Hayes MT. Parkinson’s Disease and Parkinsonism [J]. Am J Med，2019，132（7）：802-807.
[13] Pitcher TL，Myall DJ，Pearson JF，et al. Parkinson’s disease across ethnicities：A nationwide study in New Zealand [J]. Mov Disord，2018，33（9）：1440-1448.
[14] van Wamelen DJ，Taddei RN，Calvano A，et al. Serum uric acid levels and non-motor symptoms in Parkinson’s disease [J]. J Parkinsons Dis，2020，10（3）：1003-1010.
[15] 刘江红，李凯，李宁，等.帕金森病及快动眼期睡眠行为障碍患者血浆尿酸水平的关系[J].中国医药导报，2018， 15（14）：92-94.
[16] Dong X，Zheng D，Nao J. Measurement of serum cystatin C：A valuable tool for evaluating dyskinesia in Parkinson’s disease [J]. Neurosci Lett，2019，705（2）：172-176.
[17] 邢效如，郝雅男，孙志，等.帕金森病患者血清胱抑素C，β-淀粉样蛋白1-42检测的临床意义[J].现代生物医学进展，2020，20（8）：1561-1564，1568.
[18] Murray LK，Jadavji NM. The role of one-carbon metabolism and homocysteine in Parkinson’s disease onset，pathology and mechanisms [J]. Nutr Res Rev，2019，32（2）：218-230.
[19] 杨玉杰，戚志强，陆敏艳，等.同型半胱氨酸与帕金森病的临床相关性研究[J].中华老年心脑血管病杂志，2018， 20（3）：305-306.
[20] Fan X，Zhang L，Li H，et al. Role of homocysteine in the development and progression of Parkinson’s disease [J]. Ann Clin Transl Neurol，2020，7（11）：2332-2338.
[21] 杨静，董海蓉，戚志强，等.帕金森病患者血清尿酸水平与病程和病情严重程度的相关性研究[J].中华老年心脑血管病杂志，2019，21（12）：1322-1324.
[22] 徐金敏.胱抑素C在帕金森病进展过程中的作用初步研究[D].苏州：苏州大学，2014.
[23] Xiong KP，Dai YP，Chen J，et al. Increased serum cystatin C in early parkinson’s disease with objective sleep disturbances [J]. Chin Med J（Engl），2018，131（8）：907-911.
[24] 郝智军，李英杰，孔祥芬，等.神经内科住院患者血清同型半胱氨酸，叶酸和维生素B12水平分析[J].临床误诊误治，2020，33（3）：99-102.
[25] 郭敏，贺冠强，朱海生，等.血清同型半胱氨酸、尿酸水平与帕金森病的相关性分析[J].湖南中医药大学学报，2018（38）：1023.
[26] 杨静，董海蓉，戚志强，等.帕金森病患者血清同型半胱氨酸水平与病程和病情严重程度的相关研究[J].中华老年心脑血管病杂志，2019，21（7）：96-97.